Bevacizumab (Avastin®) 為一個抑制血管內皮細胞生長因子（vascular endothelial growth factor，簡稱VEGF）的重組型單株抗體，可抑制腫瘤細胞的血管新生進而抑制腫瘤細胞生長與轉移。而在2004、2005 年美國食品藥物管理局陸續發布有關可能因使用bevacizumab 導致動脈血栓梗塞事件發生的安全警訊，發現使用bevacizumab 可能增加腦梗塞、短暫性腦部缺血事件的風險。本案例為一64 歲女性轉移性結腸直腸癌患者，疑似因使用bevacizumab 導致急性腦血管栓塞，藉此案例回顧文獻，探討使用bevacizumab 導致腦血管栓塞可能的原因與危險因子。
 

Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody directed against vascularendothelial growth factor (VEGF). It can inhibit the process of angiogenesis and then interfere with a tumor’s ability to grow and metastasis. In 2004 and 2005, FDA issued warnings to healthcare providers that there is an increased risk of serious arterial thromboembolic events related to bevacizumab, including cerebrovascular accident and transient ischemic attacks. This is a case of 64-years-old woman with metastatic colorectal cancer who developed an acute cerebral embolism after bevacizumab plus irinotecan-based chemotherapy.We conducted a literature review and discussed bevacizumab-related cerebral embolism. Clinicians should use bevacizumab with caution in those who had high risk of vascular thrombosis, including age older than 65 years, history of cardiovascular disease or cardiovascular thrombosis events.